MIC of pradofloxacin against aerobic bacteria

back

Pradofloxacin MIC data for the aerobic pathogens from European strains

Organism

Period

n

MIC Range

MIC50

MIC90

(µg/ml)

Staphylococcus intermedius

2004-2007

964

0.002 - 8

0.125

0.062

2001-2003

317

≤ 0.016 - 4

0.125

0.125

2001-2007

1281

0.002 - 8

0.125

0.125

E. coli

2004-2007

145

0.008 - 16

0.25

0.062

2001-2003

163

≤ 0.016 - 8

0.125

0.031

2001-2007

308

0.008 - 16

0.25

0.062

Pasteurella multocida

2004-2007

204

0.002 - 0.062

0.016

0.016

2001-2003

119

0.008 - 0.062

0.016

0.016

2001-2007

323

0.002 - 0.062

0.016

0.016

 

The MICs of the aerobic bacteria are consistent between the sampling periods, thus the larger data set of 2001 to 2007 can be considered as representative of pradofloxacin susceptibility of these pathogens.

Whilst there is no difference in susceptibility across the sampling period, it is important to note that other fluoroquinolones licensed for use in dogs and cats were used in the same period, and that this has not impacted on resistance to pradofloxacin in any way.

Veraflox® was highly active against common Gram-positive and Gram-negative veterinary bacterial pathogens isolated from dogs and cats in Europe. The low MIC values of European field strains were consistent with the results of a U.S. study, which compared the in vitro activity of amoxicillin/clavulanic acid, pradofloxacin and other fluoroquinolones (difloxacin, enrofloxacin, marbofloxacin and orbifloxacin) to selected pathogens collected between 1996 and 1999 in the U.S. 10.

Veraflox® is highly active against common Gram-positive and Gram-negative veterinary bacterial pathogens, and the susceptibility of veterinary pathogens to pradofloxacin can be considered very similar in Europe and the United States 8, 10.

Rate this page

latest documents

3rd row with links